Opportunistic Infections in People Living with Human Immunodeficiency Virus Initiating Antiretroviral Therapy in Kinshasa, Democratic Republic of Congo

Research Article

Austin J Infect Dis. 2022; 9(3): 1073.

Opportunistic Infections in People Living with Human Immunodeficiency Virus Initiating Antiretroviral Therapy in Kinshasa, Democratic Republic of Congo

Thérèse Kaseka Ntumba1, Berry Ikolango Bongenya1,2, Lambert Omombo Losenga1, Grace Ipaya Booto1, Noëlla Makela Dikati1, Rosalie Djamba Dembo1, Stéphanie Mauwa Selenge1, Jocelyn Ewuti Nonga3, Candide About Kabamba3, Benoit Obel Kabengele4, Marie-Thérèse Ayanne Safi Sombo3, Guy Makila Mabe Bumoko3, Erick Ntambwe Kamangu*1,5

1HIV/AIDS Focus, Research Group, Kinshasa, Democratic Republic of Congo

2Faculty of Medicine, Bel Campus Technological University, Kinshasa, Democratic Republic of Congo

3Department of Neurology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo

4Department of Internal Medicine, University Clinic, Faculty of Medicine, University of Kinshasa, Democratic Republic of Congo

5Service of Molecular Biochemistry, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo

*Corresponding author: Erick Kamangu N, Service of Molecular Biochemistry, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo

Received: September 26, 2022; Accepted: October 21, 2022; Published: October 28, 2022

Abstract

Background: Opportunistic infections, which are still a major problem in the care of People Living with HIV (PLHIV), occur in situations of immunosuppression.

Objective: The objective of this study was to determine the profile of Opportunistic Infections in People Living with HIV starting Antiretroviral Treatment (ART) in Kinshasa during the Dolutegravir era.

Methods: The present study is a descriptive cross-sectional study to determine the profile of OIs among PLHIV starting ART in Outpatient Treatment Centers (OTC) in Kinshasa. Sixteen OTCs had been included in the study. The patient inclusion period in the study was from October 04, 2021 to February 15, 2022. The population of the present study was patients over the age of 18 at inclusion, infected with HIV-1 and starting ART in a selected OTC.

Results: 119 patients were included in this study respecting the inclusion criteria. 56.3% of patients included are women. The mean age on D0 is 39.87 ± 12.36 years. The most represented age group is that of 36 to 45 years with 37 patients (31.9%). The Opportunistic Infections most found in these PLHIV are: Malaria with 54 cases (45.4%), Tuberculosis (29.4%) and Cutaneous pruritus (23.5%).

Conclusion: In this cohort of patients starting ARV treatment in Kinshasa, the most common opportunistic infections are Malaria, Tuberculosis and Cutaneous Pruritus.

Keywords: Opportunistic infections, ART initiation, PLHIV, Kinshasa

Abbreviations

ART: Antiretroviral Treatment; ARV: Antiretroviral; DRC: Democratic Republic of Congo; DTG: Dolutegravir; HIV: Human Immunodeficiency Virus; OI: Opportunistic Infection; OTC: Outpatient Treatment Center; PLHIV: Person Living with Human Immunodeficiency Virus

Introduction

The control of the infection with the Human Immunodeficiency Virus (HIV) knows today great hopes in patients care and management. Indeed, the advent of Anti Retroviral Treatments (ART) has made it possible to modify the natural history of the infection. The ARTs used today allow a significant improvement in the survival of People Living with HIV (PLHIV), a slowing down of immune degradation, as well as a spectacular reduction in the frequency of Opportunistic Infections (OI) [1,2]. The latter constitute the main part of the symptomatology of HIV infection responsible for a heavy mortality and morbidity of PLHIV, especially in developing countries [2]. Most OIs respond to specific treatment. The effectiveness of this treatment is closely linked to the precocity of its initiation and to immune restoration thanks to the triple therapy [3].

OIs occur in PLHIV in situations of immunosuppression that are often caused by late treatment or rupture of Antiretroviral (ARVs). ART makes it possible to make the viral load permanently undetectable and to maintain or restore immunity, which means that in the absence of treatment or when the virus becomes resistant; the multiplication of the virus is therefore inevitable and people face a drop in their immune defenses leading to immunodeficiency [4]. It is in this situation that OIs are declared and lead to Acquired Immunodeficiency Syndrome (AIDS).

In sub-Saharan Africa, which is the region most affected by HIV infection, the number of studies on HIV and related infections conducted over the past 25 years is very low compared to Europe and America [5]. In the Democratic Republic of Congo (DRC), OIs are still a major problem in the care of PLHIV [6]. In different centers, this management is often limited to the treatment of OIs. Some local studies have shown that Tuberculosis, Candidiasis, pneumonia and malaria are the most common infections in the population [7-11]. Nevertheless, knowledge about OIs at the start of ART is still limited in Kinshasa, especially since the introduction of Dolutegravir in the care of PLHIV.

Hence the objective of this study is to determine Opportunistic Infections in People Living with HIV starting Antiretroviral Treatment in Kinshasa in the era of Dolutegravir.

Methods

Study Design, Patient and Sample Setting

The present study is a descriptive cross-sectional study to determine the profile of Opportunistic Infections (OI) among People Living with HIV (PLHIV) who starts ART in HIV Outpatient Treatment Centers (OTC) in Kinshasa. Sixteen (16) OTCs were included in the study because of their expertise in the care of PLHIV and their accessibility [12]. The patient inclusion period was from October 04, 2021 to February 15, 2022.

Data on opportunistic infections were recorded on the study sheets previously tested by the study team.

Study population

The population of the present study was patients over 18 years of age at inclusion, infected with HIV-1 and initiating ART in a selected OTC during the inclusion period. Patients were included on the following criteria: to be diagnosed as PLHIV at the OTC, to be at least 18 years old at inclusion and naïve to ART.

Parameters of interest

The parameters of interest monitored for the present study were age, sex, opportunistic infections and conditions found in PLHIV as well as clinic of patients at the inclusion (D0).

Operational definitions

An opportunistic infection is an infection due to germs that are usually not very aggressive but whose pathogenicity is amplified by the patient’s deficient immune system, his sensitivity to infections.

Ethical consideration

This study has been approved as a whole by the research ethics committee of the School of Public Health, Faculty of Medicine, University of Kinshasa (ESP/CE/115/2021). Authorization to access the OTCs has been taken from the managers of the various centers included. Prior to inclusion, fully informed consent was obtained from each participant.

Statistical analyzes

The analyzes were carried out using SPSS software version 26 (Statistical Package for Social Sciences, IBM). Only available data were analyzed, missing data were considered completely random. Correlations were sought using Pearson’s correlation test.

Results

One hundred and nineteen (119) patients were included in this study respecting the inclusion criteria. Fifty-two (52) patients, or 43.7%, included in the study are men while 67 patients (56.3%) are women; thus giving a sex ratio of 1.29 in favor of women.

The average age of patients included on D0 is 39.87 ± 12.36 years with extremities of 18 to 69 years. The most represented age group is that of 36 to 45 years with 37 patients (31.9%) followed by that of 26 to 35 years with 24 patients (20.7%), that of 46 to 55 years with 22 patients (19.0%) and that of 18 to 25 years with 19 patients (16.4%). These data are presented in Table 1.